Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.
09 February 2016 | Treatment Action Group
Our team in collaboration with the WHO Global Hepatitis Program is organizing an innovation contest on hepatitis B and C testing. The purpose of this contest is to identify innovative examples of delivering hepatitis B and C testing that will be highlighted within the 2016 WHO Hepatitis Testing Guidelines.
19 January 2016 | Social Entrepreneurship for Sexual Health
The benefits of screening prison inmates for infection with the hepatitis C virus and treating those who test positive for the infection would extend far beyond the prison population.
24 November 2015 | Eurekalert Inf Dis
Today, EASL and HIV in Europe announce a consensus definition of late presentation for viral hepatitis. The announcement coincides with the European AIDS Conference in Barcelona and aims to encourage policy makers, health professionals, public health institutions and civil society organisations to implement
this definition to improve the European surveillance of and response to the viral hepatitis epidemic.
26 October 2015 | EASL & HIV in Europe
A new study suggests massive under reporting may occur within the system set up by the US Centers for Disease Control and Prevention to estimate the incidence of acute hepatitis C virus infection. A research team found that less than 1 percent of a group of acute HCV patients in Massachusetts had been reported to the CDC, largely because required data was either not available or did not meet CDC definitions for acute HCV infection.
02 July 2015 | Eurekalert Inf Dis
This report, prepared by Professor David Goldberg and supported by Bristol Myers-Squibb, looks at the linkages between excessive alcohol consumption and hepatitis C, and explores how excessive alcohol consumption can act as a barrier to people with hepatitis C being considered for, receiving and the benefit of treatment for hepatitis C.
24 June 2015 | HCV Action
At this year's Digestive Disease Week, investigators discussed issues related to screening efforts, the natural history of HCV infection, the safety and efficacy of the next wave of antiviral agents, access to care, and affordability of treatment.
17 June 2015 | Medscape
The increase in reports reflects significant improvements in testing for hepatitis and other blood borne viruses (BBV) in prisons, which in a major change is moving from an ‘opt-in’ to an ‘opt-out’ policy to help reduce transmissions.
16 June 2015 | Public Health England press release
At a meeting in Rio de Janeiro, the Executive Board announced it would as a first step focus investments in three areas: improving antiretroviral therapy for adults in low and middle-income countries; enabling the expanded use, or "scale-up", of first pre-exposure prophylaxis (PrEP) as a means of preventing HIV transmission; and the development of better tools to diagnose hepatitis C virus (HCV), in particular for people who are co-infected with HIV/HCV.
08 June 2015 | UNITAID
Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.
20 May 2015 | European Liver Patients Association